Media headlines about Curis (NASDAQ:CRIS) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Curis earned a news sentiment score of 0.10 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.3193026075433 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Shares of Curis traded up $0.03, hitting $1.87, during trading on Thursday, MarketBeat.com reports. The company’s stock had a trading volume of 148,700 shares, compared to its average volume of 428,111. The company has a debt-to-equity ratio of 2.24, a quick ratio of 3.60 and a current ratio of 3.60. Curis has a fifty-two week low of $1.57 and a fifty-two week high of $11.35. The stock has a market cap of $58.96 million, a price-to-earnings ratio of -1.04 and a beta of 1.28.
Curis (NASDAQ:CRIS) last released its quarterly earnings results on Thursday, May 3rd. The biotechnology company reported ($0.35) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.45) by $0.10. Curis had a negative return on equity of 247.46% and a negative net margin of 472.13%. The business had revenue of $2.47 million for the quarter, compared to analysts’ expectations of $2.30 million. equities research analysts predict that Curis will post -1.67 EPS for the current year.
A number of brokerages have commented on CRIS. Robert W. Baird reduced their price objective on Curis to $30.00 and set an “outperform” rating on the stock in a research note on Monday, May 7th. Zacks Investment Research upgraded Curis from a “hold” rating to a “buy” rating and set a $2.50 price objective on the stock in a research note on Tuesday, May 8th. Finally, ValuEngine upgraded Curis from a “sell” rating to a “hold” rating in a research note on Thursday, May 31st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $22.50.
Curis Company Profile
Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.